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Abstract
Background: The world’s population has been growing exponentially, however, cur-
rently the choices for male contraception are limited. This review explores ongoing 
researches on male contraceptives. 
Method: A literature search was conducted on PubMed, Cochrane, and Google Scholar 
on March 2015. 
Results: There are 15 research done on non-hormonal male contraceptives, 2 of which are 
already widely used and the other 2 are undergoing clinical trials. Hormonal contracep-
tives are provided in two regiments, testosterone alone, and testosterone with progestins. 
Currently, no hormonal contraceptives are available for men. 
Conclusion: There are a variety of possible methods for male contraception. Non-
hormonal methods, such as RISUG and Gandarusa are sent through clinical trials, and 
may be available in the near future. There are still no hormonal contraceptives for men 
that are ready for use.
Keywords: male contraception, hormonal contraceptives, non-hormonal contraceptives
1. Introduction
The world’s population has been growing exponentially in the recent decades is expected to 
reach 9 billion in 2050. Considering the current difficulties in managing health and poverty, 
contraception is becoming increasingly important [1, 2].
Contraception is the intentional prevention of conception or pregnancy by various methods; 
barrier methods, hormonal contraception, intrauterine devices, sterilization and behavioral 
methods. Of these methods, only two are available for men, the male condom (barrier), and 
vasectomy (sterilization). The male condom is an effective method of contraception with 
the added benefit of prevention of STIs, however relies on discipline and availability of the 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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condom at the time of intercourse. A vasectomy doesn’t depend on the occurrence of inter-
course, but has poor reversibility rates and is therefore not ideal for men who still plan on 
having children [1, 3–5].
Long term, reversible male contraceptives are currently being developed. Male contraceptives 
are aimed to interfere with normal spermatogenesis, or motility, orientation, and binding to 
ovum. This paper reviews previous studies on male contraceptives to give a general picture 
of the possibilities and current available methods.
2. Methods
A literature search was conducted on PubMed in March 2015 with the search terms male 
AND contraceptives* and male AND infertility* between 2010 and 2015. Titles and abstracts 
were manually scanned by one researcher and those related to male contraceptives were cho-
sen. When information was found to be lacking, more searches were done with specific terms 
and no time limit, for example “CDB 4022”.
Further searches were done on Google Scholar with Indonesian terms “kontrasepsi pria” 
and results were once again manually searched for articles related to male contraception. All 
searches were limited to articles that were available for free.
3. Results
3.1. Spermatogenesis
Spermatogenesis is the formation of sperm from primordial germ cells. At puberty, spermato-
genic germ cells (spermatogonia) produce BMP8B which cause the germ cells to differenti-
ate. Spermatogonia are attached to Sertoli cells, which nourish and protect the cells as they 
undergo spermatogenesis [6].
Spermatogonia undergo several divisions and forms various forms of Spermatogonia A, 
intermediate spermatogonia and spermatogonia B. Spermatogonia A1 are stem cells and 
can continue to divide into more spermatogonia, thus spermatogenesis occurs continuously. 
Spermatogonia B divides into primary spermatocytes, which undergoes meiotic divisions to 
form round, haploid cells known as spermatids [6].
Spermatids then go through spermiogenesis to form mature sperm. During spermiogenesis, 
Golgi apparatus forms the acrosome that caps the nucleus. Flagellum is formed on the oppo-
site side of the nucleus. The nucleus itself is condensed, and mitochondria forms a ring at the 
base of the tail. Once all of these changes have taken place, mature spermatozoa is released 
into the lumen, a process called spermiation [6].
In humans the process from spermatogonia to spermatozoa takes up to 65 days. About 100 mil-
lion sperm are produced every day, and each ejaculation contains up to 200 million sperm. Each 
day, some 100 million sperm are made in each human testicle, and each ejaculation releases 
200 million sperm. Unused sperm are either resorbed or passed out of the body in urine [6].
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3.2. Nonhormonal contraceptive
Nonhormonal male contraception targets sperm production, maturation and/or function, 
without interrupting the hormonal pathway. Many nonhormonal targets in the spermatogen-
esis and fertilization process has been identified, and contraceptive opportunities have been 
tested and implemented [7].
3.2.1. Condoms
Condoms prevent pregnancies by blocking the path of semen into the cervix. With correct use, 
the efficacy is 97%, with the added benefit of prevention against STIs and HIV. However with 
typical use, failure rates are as high as 12%. The correct use of condom refers to application of 
condom before vaginal penetration, preferably before any penile-vaginal contact. On applica-
tion, the tip of the condom must be pressed to release trapped air and consequently provide 
space for semen [7].
Drawbacks of this method apart from its failure rates are latex allergies, possibility of break-
age, and decreased pleasure for some couples [7].
3.2.2. Vasectomy
Vasectomy is a procedure in which the vas deferens are divided and ligated so as to pre-
vent flow of sperm from testis. This is an outpatient procedure, conducted with local anes-
thesia with minimal side effects. Following vasectomies, pregnancy rates drop to below 1%. 
However reversibility rates after vasectomy is less than 50%. There is no effect on libido [7].
3.2.3. Reversible inhibition of sperm under guidance (RISUG)
RISUG is a method of contraception directed at destruction of sperm as it passes through the 
vas deferens. RISUG is applied by injection of steric maleic anhydride (SMA) and dimethyl 
sulfoxide (DMSO) into the vas deferens. Within the next 72 h, RISUG forms electrically 
charged precipitates in the lumen, with positive charges dominating [7]. This forms an 
acidic environment. The precipitate then layers the lumen wall, implanting themselves on 
the microfolds on the vas deferens’ inner walls. Sperm that pass through the RISUG injected 
vas deferens, suffer ionic and pH stress, causing acrosomal damage, rendering them unable 
to fertilize oocytes [5, 8]. Studies so far have shown RISUG to be 100% effective. Because 
of the time needed for action, however, condom use is suggested in the first 10 days after 
injection [8].
RISUG can be flushed out with intravasal injections of sodium bicarbonate, which will reverse 
its infertility effects, as has been shown in mice [9]. Reversibility testing in humans has not 
been performed.
There has been no serious side effect within 10 years after RISUG injections in humans. Scrotal 
swelling may occur after injection, but resolves on its own. A study that studied RISUG’s side 
effects on the prostate found that there was no increased risk of developing prostatic diseases 
even after a period of 8 years [9].
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Smart RISUG [9] comprises of iron oxide-copper-styrene maleic anhydride-dimethyl sulfox-
ide (Fe
3
O
4
–Cu–SMA–DMSO), and has been shown to give better spermicidal action in vitro 
and in vivo in rats. Copper has been known to displace molecules such as zinc from sperm 
membrane, decreasing their potential to fertilize. Studies need to be conducted on toxicity of 
this new drug before application on humans [9].
3.2.4. Ultrasound
Application of low intensity ultrasound to the scrotum can elevate tissue temperatures in the 
testes [10, 11]. Spermatogenesis cannot occur in body temperature, which is why the human 
testes is suspended in the scrotal sack with a network of blood vessels to allow for cooling. 
Studies show that heat stress on the testes lead to apoptosis of germ cells [12]. In the past, local 
application of heat to the testes, such as immersing in a hot baths, has been used as a method 
of contraception [1].
Experiments on monkeys have shown that ultrasound exposure to the scrotum was 93% effec-
tive in inducing azoospermia in 1–2 weeks with sperm counts rebounding to normal after 
7 weeks [11]. Intensity of ultrasound required to cause infertility depended on testes size 
[10, 11]. Heat treatment during therapy by dipping scrotum in 37C water or saline increased 
ultrasound potential as seen in rats and monkeys [10]. There are no side effects noted in ultra-
sound treatments, however there is concern that heat treatment may cause DNA damage in 
consecutive sperm productions [10, 11].
3.2.5. Vaccines
Contraceptive vaccines are developed under the concept of targeting sperm specific antigens 
[1, 13]. Vaccination with these sperm antigens (recombinant/synthetic peptide/DNA) has been 
found to cause reversible contraceptive effects in animals through formation of systemic and 
local antisperm antibody responses. The sperm antigens which have been examined for con-
traceptive effect include: FA-1, YLP12, LDH-C4, P10G, A9D, SP56, 80 kDaHSA, Eppin, and 
Izumo. There has been no contraceptive vaccine tested on men [13, 14].
Eppin is a protein secreted by the epididymis for sperm maturation [1, 14]. It is found on 
sperm surface and aids in fertilization. The vaccinated subjects produce antibodies against 
Eppin molecules, thus impairing sperm maturation and its capability to fertilize [13, 14].
An in vivo study of Eppin in monkeys resulted in 78% of the monkeys becoming infertile. 
Seventy one percent of them regained fertility after 450 days. Adjuvants were required every 
3 months to maintain antibody levels. Studies are being conducted to improve safety, efficacy 
and reversibility before application in humans [14]. So far, no other in vivo studies have been 
conducted on other contraceptive vaccines.
3.2.6. Indenopyridines
CDB-4022, an indenopyridine is being studied as a potential oral contraceptive for men [15]. 
This compound was found to affect sertoli and germ cells, causing alterations in sertoli-germ 
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cell junctions and causing apoptosis of germ cells in rats. It causes irreversible azoosper-
mia in rats, but reversible oligospermia in monkeys. There are no changes to serum LH and 
Testosterone levels, but increased levels of FSH attributed to reduction of inhibin B caused by 
destruction of germ cells [15]. There were no toxicities noted. Efficacy and reversibility are 
missing on literature.
3.2.7. Adjudin
Adjudin is derived from an anticancer drug, lonidamine. Lonidamine was found to be anti-
spermatogenic, thus causing infertility. However, it also caused several side effects such as 
muscular pain, testicular pain, and liver damage. To attain the anti-fertility functions with-
out the toxicity, Adjudin was developed. Adjudin targets adherence junctions between 
Sertoli cells and spermatids, causing early spermiation. One hundred percent infertility was 
achieved 5 weeks after administration of adjudin and fertility returned 11 weeks after treat-
ment. Serum testosterone, FSH and LH remained normal, however, liver and skeletal muscle 
atrophy occurred in one third of the rats. To overcome this, adjudin was administered with 
an FSH mutant, which successfully bypassed the liver and muscle effects. Unfortunately, this 
made adjudin too costly as a contraceptive [16].
A study was conducted by Wang et al. [17] to assess the possibility of adjudin to be as a sper-
micide. In vitro evaluation showed that adjudin was found to significantly limit sperm motil-
ity and viability by targeting sperm mitochondria [17].
3.2.8. Gamendazole
Gamendazole is also derived from ionidamine, and causes infertility by targeting Sertoli cells 
[18, 19]. A study in rats showed that administration of a single dose of gamendazole resulted 
in 100% infertility 4 weeks post treatment, however, reversibility was only 57%. At half the 
dose, only 67% infertility was achieved, albeit with 100% reversibility. There were no changes 
in LH and testosterone levels, but a slight transient increase in FSH was observed due to 
depletion of inhibin B. There were no noticeable side effects, however at there was 60% mor-
tality in rats given 200 mg/kg gamendazole, but not at any lower dose. Another option being 
investigated is administration of daily gamendazole at 1 mg/kg to achieve 100% infertility 
with 100% reversibility. Human trials are still pending [18–20].
3.2.9. Calcium channel blockers (CCBs)
Calcium is required for sperm motility, capacitation and acrosome reactions. Uptake of cal-
cium is facilitated by calcium channels on sperm membranes. Calcium channel blockers 
inhibit calcium influx into sperm cell and thus impair fertility. Although there are many CCBs 
available, none has been tested as contraceptives because of the impracticality of using antihy-
pertensive agents as contraceptives.
Calcium entry into sperm is also facilitated by transmembrane CATSPER channels which 
exist primarily in the testis. Blockade of CATSPER channels is a plausible mechanism for con-
traceptives, however as of today, there are still no known antagonists [21].
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3.2.10. Retinoic acid inhibitor
Vitamin A is crucial for normal spermatogenesis. It is transported as retinol and synthesized 
into retinoic acid in the testis. Retinoic acid works through Retinoic Acid Receptors (RAR) on 
Sertoli cells. Retinoic acid inhibition and retinoic acid receptor blockers inhibit spermatogen-
esis and are easily reversed [22–26].
WIN 18,446 inhibits testicular retinoic acid biosynthesis through inhibition of aldehyde dehy-
drogenase 1A2 in vitro in humans. Administration of WIN 18,446 in dogs and monkeys have 
been found to induce azoospermia. Testicular biopsies show complete arrest of spermatogen-
esis [22, 25]. In the 1960s, administrations of oral WIN 18,446 in men have shown adequate 
contraceptive effects. These effects were completely reversible upon cessation of treatment. 
Reduced testicular volume was observed, but serum testosterone remained unchanged [26].
WIN 18,446 caused no liver or kidney toxicities. However when men taking WIN 18,446 con-
sumed alcohol, they develop a “disulfiram reaction,” which consists of nausea, vomiting, pal-
pitations and sweating. This is because inhibition of aldehyde dehydrogenase 1A2 interferes 
in the metabolism of alcohol [25, 26]. Studies are being conducted to find a compound which 
inhibits retinoic acid synthesis without affecting alcohol metabolism [26].
3.2.11. Retinoic acid receptor antagonists
BMS-189453 is a synthetic retinoic acid receptor antagonist. It binds to retinoic acid receptors 
(RARs) but do not activate them. The testis and epididymis, especially sertoli cells are rich in 
RARs. Introducing a RAR antagonist was found to induce the same effects as Vitamin A defi-
ciency in terms of apoptosis of germ cells and inhibition of spermatogenesis [23, 24].
A research done with low dose BMS-189453 on mice fertility showed 100% efficacy in induc-
ing azoospermia. This is followed by 100% reversibility after 4 weeks of stopping treatment. 
Toxicity analysis showed no hematology or blood chemistry abnormalities, and tissue pathol-
ogy was isolated to the testis, where there is failure of spermatogenesis, spermatid alignment, 
and sloughing of germ cells [24].
3.2.12. Gandarusa
Gandarusa is derived from the plant Justicia gendarussa [27, 28], which has been used by 
many tribes in eastern Indonesia as a contraceptive medicine. The roots and leaves are boiled 
in water and the water is then consumed twice a month to elicit contraceptive effects. This 
plant is also used as herbal medication for pain and inflammation. Gandarusa has since been 
standardized and is now available in pill form [27].
Gandarusa was found to affect spermatogenesis in rats as well as human. The proposed 
mechanism of Gandarusa is weakening of the sperm’s hyaluronidase activities required 
for penetration of sperm into ovum, thus preventing fertilization [27]. Animal studies have 
shown no liver or kidney toxicities [28]. This drug is currently undergoing phase III clinical 
trials. There is no available data on efficacy of gandarusa as a contraceptive in humans, as well 
as reversibility rates and effects on libido.
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3.2.13. Gossypol
Gossypol is found in cotton plant genus Gossypium [1, 29]. In 1972, a research on the effects 
of gossypol on 10,000 men were observed. Gossypol was found to be 99.07% effective as a 
contraceptive. Gossypol has been reported to interfere in hypothalamus-pituitary axis, dis-
rupt spermatogenesis and reduce sperm motility. In 1996, a study on the effects of gossypol 
in vitro found that Gossypol decreases sperm motility by inhibiting cAMP production. There 
are no noted side effects. However, reversibility rates are only 80% [29].
3.3. Hormonal contraceptives
The gist of hormonal contraception in men is altering the hormonal pathway so that spermato-
genesis does not occur. Gonadotropin releasing hormone (GnRH) from the hypothalamus 
stimulates the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
from the pituitary. FSH stimulates sertoli cells to begin spermatogenesis, while LH stimulates 
Leydig cells to produce testosterone. Testosterone then provides negative feedback to hypo-
thalamus and pituitary, suppressing their activity and subsequently its own production [4].
Male hormonal contraception focuses on suppressing hypothalamus and the pituitary action 
to inhibit spermatogenesis. This has been done by provision of testosterone alone as well as 
testosterone and progestins [4].
3.3.1. Testosterone alone
Oral preparations of testosterone that are safe for consumption are not readily available. 
Long-acting injections and implants are being developed as alternatives. Testosterone gel and 
patches are in development, however, they are costly and require frequent application thus 
making them unaffordable as a commercial contraceptive [30].
Common side effects of testosterone are acne, oily skin, mood changes, increased hemoglo-
bin, weight gain, decreased testicular volume, gynecomastia, and dyslipidemia. Long term 
effects of testosterone supplementation on the prostate are still unclear. Other considerations 
in using testosterone preparations are the possible misuse as anabolic steroids [3].
3.3.1.1. Testosterone enanthate (TE)
TE is a long acting preparation that requires weekly administration through intramuscular 
injections [31]. In a study by WHO, azoospermia is achieved by an average of 3 months in 70% 
of men receiving 200 mg TE weekly. Once azoospermia is reached, TE can be effectively used 
alone as a contraceptive; with 0.8% failure rate. Reversibility is 100% within an average of 
4 months after discontinuation. Side effects of TE were reductions in HDL levels and testicular 
volumes, albeit reversible after cessation of use.
This method has a few drawbacks. First, not all men receiving this therapy will become azo-
ospermic. Second, weekly injections are required. Third, there were worrying side effects 
regarding to HDL levels and testicular volume. Finally, it requires 3–7 months to achieve azo-
ospermia, therefore requiring another form of contraceptive until azoospermia is achieved.
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3.3.1.2. Testosterone undecanoate (TU)
TU is formulated in long acting depot preparations with a half-life of 70 days that can be 
administered intramuscularly in intervals of 4–8 weeks [3]. A clinical trial in China reported 
that 95% of test subjects achieved azoospermia, defined as sperm concentration < 1 million 
per milliliter. Pregnancy rates were at 1.1%. Sperm count was reversed after 15 months of 
stopping therapy. A European clinical trial by WHO produced similar results. However, trials 
were stopped due to reports of side effects such as mood swings.
3.3.1.3. 7α-Methyl-19-nortestosterone (MENT)
MENT is a synthetic androgen five times more potent than testosterone [3, 31]. MENT was 
developed to replace testosterone for contraceptive use because of the large amount of testos-
terone required to achieve long term infertility. Also because it is resistant to 5α-reductase, 
there is less prostate stimulation. However, substituting testosterone with MENT led to a 
decrease in bone density.
MENT has been introduced in implant form as a contraceptive and has been found to cause 
azoospermia in two thirds of men receiving it. To improve its efficacy researchers combined 
it with etonogestrel implants and levonorgestrel implants. Results were the same as with 
MENT alone. In addition, men receiving MENT and etonogestrel experienced loss of libido. 
Research are continuously being conducted on a form of dosing that will attain a higher rate 
of azoospermia with minimal side effects.
3.3.2. Combination therapy
Exogenous progestins combined with testosterone provide better suppression of gonadotro-
pins, thus more effective at producing azoospermia at lower doses [3]. There has been sev-
eral researches combining various progestins with androgens for male contraceptive. Among 
them are:
• Depot medroxyprogesterone acetate (DMPA) + TE (efficacy 98%) [3].
• Antiandrogenic Progestogen Cyproterone Acetate (CPA) + TE [3].
• Androgenic progestin Norethisterone (NET) + TU (efficacy 92%) [3].
• Oral Levonorgestrel (LNG) + testosterone patches (efficacy < 60%) [3].
• LNG + TE (efficacy 93%) [3].
• Synthetic progestin Desogestrel (DSG) + TE (efficacy 100%) [3].
• MENT implant + Jadelle implant (efficacy < 60%) [31].
Data on reversibility, effect on libido of these tested regiments were not found on the 
literature.
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4. Discussion
In the past, male contraceptives have been acknowledged. There are few commonly applied 
methods of male contraception such as local application of heat, consumption of herbal 
medicines, coitus interruptus, vasectomy, and male condoms. Each of these methods has had 
drawbacks that cause them to only be used by a minority of the population. Heat application 
and herbal medicines lack evidence of overall efficacy. Coitus interruptus has a 12% failure 
rate even when practiced correctly. Condoms depend a lot on correct use, and are rendered 
useless in the case of breakage. Vasectomy has less than 50% reversal rates. There is still no 
long term, reversible contraceptive available for men.
Method Efficacy Mechanism Effect on 
libido
Reversibility Side effects Additional 
information
Condom 97% Forms barrier to 
prevent sperm from 
entering female 
reproductive tract 
(FRT)
No effect 100% Possible latex 
allergy in 3% of 
men, decreased 
sexual pleasure
Highly effective 
in preventing 
STI
Vasectomy 99% Occlusion of vas 
deferens to prevent 
sperm from being 
ejaculated in semen
No effect 50% Scrotal pain
Ultrasound 93% Produces thermal 
effect on testes
No effect 100% after 
7 weeks
No side effects Intensity and 
duration of 
ultrasound 
depends on 
size of testes
There are 
risks of DNA 
damage in heat 
treated testes
Indenopyridines – CDB-4022 appears to 
target the Sertoli cell, 
disrupting germ cell- 
sertoli time
– – Increased FSH
Adjudin 100% Adjudin affects 
fertility by disrupting 
Sertoli-germ cell 
junctions, and 
once this occurs, 
germ cells slough 
the seminiferous 
epithelium 
prematurely
No 
changes in 
testosterone, 
LH, or FSH
100% Muscle atrophy 
and liver 
inflammation
Adjudin + FSH 
mutant 
bypasses liver 
and muscle 
atrophy, but is 
costly
RISUG 100% Injection of RISUG 
into vas deferens to 
destroy sperm ability 
to fertilize
No effect 100% in 
monkeys and 
langurs
No side effects. 
Reversible 
scrotal edema 
may occur after 
injection
Phase III 
clinical trial 
(safety and 
efficacy on 
humans 
established)
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Method Efficacy Mechanism Effect on 
libido
Reversibility Side 
effects
Additional 
information
Testosterone Enanthate 70% Suppresses 
gonadotropin 
production
No effect 100% Reduced 
testicular 
volume 
and HDL 
level
Testosterone undecanoate 95% Suppresses 
gonadotropin 
production
No effect 100% Mood 
swings
Testosterone gel Suppresses 
gonadotropin 
production 
through increase 
of testicular 
testosterone
No effect 100% – Expensive
Testosterone + Progestogen Variable Suppresses 
gonadotropin 
production
– 100% –
Cited from: Blithe [30].
Table 2. Hormonal contraceptives.
Method Efficacy Mechanism Effect on 
libido
Reversibility Side effects Additional 
information
Calcium 
Channel Blocker
– Blocks Ca++ influx 
into sperm and affects 
sperm membrane 
cholesterol, thereby 
compromising 
fertility
– – – CCBs have 
never been 
tested as 
contraceptives
Gamendazole 100% 
after 
4 weeks
Affects sertoli cells No effect 57% after 
11 weeks
No side effects Causes death 
in rats at doses 
200 mg/kg
WIN 18,446 100% Suppresses 
spermatogenesis by 
inhibiting testicular 
retinoic acid 
biosynthesis
No effect 100% “Disulfiram” 
effect upon 
consumption of 
alcohol
Nausea, 
vomiting, 
palpitation 
when drinking 
alcohol
BMS 189453 100% Causes marked 
testicular 
degeneration
No effect 100% No side effects
Gossypol 99.07% Decreases sperm 
motility by inhibiting 
cAMP production
Not 
mentioned
80% No side effects Research 
conducted in 
Chinese men
Gandarusa – – – – – Undergoing 
clinical trials
Cited from: Blithe [30].
Table 1. Non-hormonal contraceptives.
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Considering numerous hormonal contraceptive methods available for women, hormonal path-
ways have been studied to develop an effective and safe male contraceptive. Disappointingly, 
no hormonal regiments have yet been approved for contraceptive use.
Non hormonal contraceptives have shown more promise. RISUG and Gandarusa are under-
going relatively successful clinical trials in terms of efficacy and safety [7]. RISUG requires 
only a single injection, which has maintained infertility for up to 10 years now. Reversibility 
also requires only a single injection, but has yet to be tested on humans. Gandarusa is available 
in pill form, giving men the choice to be an oral contraceptives. The success of these agents, 
however, depends largely on the men’s willingness to take responsibility for family planning.
A review on male contraceptives shares the same conclusion that despite the expression of 
interest and tremendous advances in research however, a modern male hormonal contraceptive 
method has remained an elusive goal. Testosterone (T) alone, or in combination with a proges-
tin currently provides the most promising lead to male hormonal contraception. The principle 
relies on enhanced negative feedback of exogenous T to suppress gonadotropins, thereby block-
ing the endocrine stimulus for the process of spermatogenesis. A serious drawback is the incon-
sistent suppression among men of different ethnic backgrounds. This has increased the quest 
for development to include other nonhormonal methods. In reality many obstacles still have to 
be overcome before an acceptable method is available [32].
To conclude, there are a variety of possible methods for male contraception. Non-hormonal 
methods RISUG and Gandarusa are undergoing clinical trials, and may be available in the 
near future. There are still no hormonal contraceptive ready to use for men (Tables 1 and 2).
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